Literature DB >> 6138046

Absorption, distribution and excretion of 3-(sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in Rats, Dogs and Monkeys and of AD-810 in Men.

K Matsumoto, H Miyazaki, T Fujii, A Kagemoto, T Maeda, M Hashimoto.   

Abstract

Disposition of 3 - (sulfamoyl[14C]methyl) - 1,2-benzisoxazole ( [14C]AD-810) in rats, dogs and monkeys after oral administration in 20 mg/kg was studied. In preliminary human studies, healthy subjects ingested 200 mg of AD-810. [14C]AD-810 was found to be completely absorbed from digestive tracts in animals, since urinary and biliary excretion accounted for virtually total recovery of dosed radioactivity. Plasma levels reached maxima at several hours after administration in all species examined and decreased exponentially. In rats, tissue levels were virtually similar to plasma levels indicating rather even distribution in the body, and tissue radioactivity disappeared with the similar rate to plasma. Autoradiographic findings on the distribution were consistent with radiometric results. Radioactivity was evenly distributed in fetus in the pregnant rat with the similar level to maternal tissue levels. Like other sulfonamide derivatives, AD-810 was markedly taken up by erythrocytes in all species. [14C]AD-810 radioactivity was mostly excreted within 48 to 72 h after administration and its major route was urine in animals. In men, excretion of unchanged AD-810 and its metabolite in urine was found to be rather slow. No significant differences were found in absorption, distribution and excretion of radioactivity after 7 consecutive daily oral dosings of [14C]AD-810 in rats.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138046

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

Review 1.  Zonisamide: a review of its use in the management of partial seizures in epilepsy.

Authors:  James E Frampton; Lesley J Scott
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 3.  The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.

Authors:  E Perucca; M Bialer
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 4.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

5.  Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.

Authors:  Shin-Ichi Ueno; Shinji Saiki; Motoki Fujimaki; Haruka Takeshige-Amano; Taku Hatano; Genko Oyama; Kei-Ichi Ishikawa; Akihiro Yamaguchi; Shuko Nojiri; Wado Akamatsu; Nobutaka Hattori
Journal:  Cells       Date:  2018-12-29       Impact factor: 6.600

6.  Zonisamide can ameliorate the voltage-dependence alteration of the T-type calcium channel CaV3.1 caused by a mutation responsible for spinocerebellar ataxia.

Authors:  Naoyuki Hara; Hiroyuki Morino; Yukiko Matsuda; Kenichi Satoh; Kouichi Hashimoto; Hirofumi Maruyama; Hideshi Kawakami
Journal:  Mol Brain       Date:  2020-11-26       Impact factor: 4.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.